A Study to Assess Bioequivalence of a New Tapentadol Extended-Release 250-mg Tablet With Respect to a Tapentadol Extended-Release 250-mg Tablet in Healthy Participants

NCT01981278 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

63

Enrollment

INDUSTRY

Sponsor class

Conditions

Healthy

Interventions

DRUG: Tapentadol ER 250-mg TRF tablet
DRUG: Tapentadol ER 250-mg PR2 tablet

Sponsor

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.